ZEISS unveils AI-powered Research Data Platform; collaboration with Boehringer Ingelheim champions the future of personalized eye care
ZEISS has unveiled its new AI-powered Research Data Platform (RDP) at ARVO 2025, marking a significant advancement in ophthalmic research. The cloud-based platform enables seamless integration of clinical and research data, allowing researchers to accelerate discoveries through AI-driven analysis.
The company has also highlighted its ongoing collaboration with Boehringer Ingelheim to develop personalized eye care solutions. This partnership focuses on earlier detection and prediction capabilities for chronic retinal diseases using AI technology.
Key features of the ZEISS RDP include:
- AI-powered tools for converting research hypotheses into quantifiable biomarkers
- Unified data management across multiple sources
- Streamlined research workflow integration with clinical systems
The platform will launch in select countries throughout 2025 following successful pilot testing. Expert talks featuring leading ophthalmologists will be presented at ARVO 2025 to discuss AI's role in future eye care practices.
ZEISS ha presentato la sua nuova Research Data Platform (RDP) alimentata dall'IA all'ARVO 2025, segnando un importante progresso nella ricerca oftalmica. Questa piattaforma cloud consente l'integrazione fluida di dati clinici e di ricerca, permettendo ai ricercatori di accelerare le scoperte grazie all'analisi guidata dall'intelligenza artificiale.
L'azienda ha inoltre sottolineato la sua collaborazione in corso con Boehringer Ingelheim per sviluppare soluzioni personalizzate per la cura degli occhi. Questa partnership si concentra sulla diagnosi precoce e sulle capacità predittive delle malattie retiniche croniche tramite tecnologia IA.
Le caratteristiche principali della ZEISS RDP includono:
- Strumenti basati sull'IA per trasformare le ipotesi di ricerca in biomarcatori quantificabili
- Gestione unificata dei dati provenienti da più fonti
- Integrazione semplificata del flusso di lavoro di ricerca con i sistemi clinici
La piattaforma verrà lanciata in alcuni paesi nel corso del 2025, dopo test pilota di successo. All'ARVO 2025 saranno presentati interventi di esperti, con importanti oftalmologi, per discutere il ruolo dell'IA nelle future pratiche di cura oculare.
ZEISS ha presentado su nueva Plataforma de Datos de Investigación (RDP) impulsada por IA en ARVO 2025, marcando un avance significativo en la investigación oftalmológica. Esta plataforma en la nube permite la integración fluida de datos clínicos y de investigación, facilitando que los investigadores aceleren los descubrimientos mediante análisis impulsados por inteligencia artificial.
La compañía también destacó su colaboración continua con Boehringer Ingelheim para desarrollar soluciones personalizadas para el cuidado ocular. Esta alianza se centra en la detección temprana y las capacidades predictivas de enfermedades retinianas crónicas utilizando tecnología de IA.
Las características clave de la ZEISS RDP incluyen:
- Herramientas basadas en IA para convertir hipótesis de investigación en biomarcadores cuantificables
- Gestión unificada de datos provenientes de múltiples fuentes
- Integración simplificada del flujo de trabajo de investigación con sistemas clínicos
La plataforma se lanzará en países seleccionados durante 2025 tras pruebas piloto exitosas. En ARVO 2025 se presentarán charlas de expertos con destacados oftalmólogos para discutir el papel de la IA en las futuras prácticas de cuidado ocular.
ZEISS가 ARVO 2025에서 새로운 인공지능 기반 연구 데이터 플랫폼(RDP)을 공개하며 안과 연구 분야에서 중요한 진전을 이루었습니다. 이 클라우드 기반 플랫폼은 임상 및 연구 데이터를 원활하게 통합하여 연구자들이 AI 주도 분석을 통해 발견 속도를 높일 수 있도록 합니다.
회사는 또한 Boehringer Ingelheim과의 지속적인 협력을 강조하며 개인 맞춤형 안구 관리 솔루션을 개발하고 있습니다. 이 파트너십은 AI 기술을 활용한 만성 망막 질환의 조기 발견 및 예측 능력에 중점을 두고 있습니다.
ZEISS RDP의 주요 기능은 다음과 같습니다:
- 연구 가설을 정량화 가능한 바이오마커로 전환하는 AI 도구
- 다양한 출처의 데이터 통합 관리
- 임상 시스템과 연구 워크플로우의 원활한 통합
이 플랫폼은 성공적인 파일럿 테스트 후 2025년 중 일부 국가에서 출시될 예정입니다. ARVO 2025에서는 AI가 미래 안구 관리에 미치는 역할을 논의하는 주요 안과 전문의들의 전문가 강연이 진행됩니다.
ZEISS a dévoilé sa nouvelle plateforme de données de recherche (RDP) alimentée par l'IA lors de l'ARVO 2025, marquant une avancée majeure dans la recherche ophtalmologique. Cette plateforme cloud permet une intégration fluide des données cliniques et de recherche, permettant aux chercheurs d'accélérer les découvertes grâce à l'analyse pilotée par l'intelligence artificielle.
L'entreprise a également souligné sa collaboration continue avec Boehringer Ingelheim pour développer des solutions personnalisées de soins oculaires. Ce partenariat se concentre sur la détection précoce et les capacités prédictives des maladies rétiniennes chroniques grâce à la technologie IA.
Les principales caractéristiques de la RDP ZEISS comprennent :
- Outils basés sur l'IA pour transformer les hypothèses de recherche en biomarqueurs quantifiables
- Gestion unifiée des données provenant de plusieurs sources
- Intégration simplifiée du flux de travail de recherche avec les systèmes cliniques
La plateforme sera lancée dans certains pays tout au long de 2025 après des tests pilotes réussis. Des conférences d'experts avec des ophtalmologistes de renom seront présentées à l'ARVO 2025 pour discuter du rôle de l'IA dans les pratiques futures de soins oculaires.
ZEISS hat auf der ARVO 2025 seine neue KI-gestützte Research Data Platform (RDP) vorgestellt und damit einen bedeutenden Fortschritt in der ophthalmologischen Forschung erzielt. Die cloudbasierte Plattform ermöglicht eine nahtlose Integration von klinischen und Forschungsdaten, wodurch Forscher Entdeckungen durch KI-gestützte Analysen beschleunigen können.
Das Unternehmen betonte zudem seine laufende Zusammenarbeit mit Boehringer Ingelheim zur Entwicklung personalisierter Augengesundheitslösungen. Diese Partnerschaft konzentriert sich auf frühere Erkennung und Vorhersage chronischer Netzhauterkrankungen mithilfe von KI-Technologie.
Wesentliche Merkmale der ZEISS RDP umfassen:
- KI-gestützte Werkzeuge zur Umwandlung von Forschungshypothesen in quantifizierbare Biomarker
- Vereinheitlichte Datenverwaltung über mehrere Quellen hinweg
- Optimierte Integration von Forschungsabläufen mit klinischen Systemen
Die Plattform wird nach erfolgreichen Pilotversuchen im Laufe des Jahres 2025 in ausgewählten Ländern eingeführt. Auf der ARVO 2025 werden Expertenvorträge führender Ophthalmologen gehalten, die die Rolle der KI in zukünftigen Augenpflegepraktiken diskutieren.
- Launch of AI-powered ZEISS Research Data Platform (RDP) showcasing technological innovation and market expansion
- Strategic partnership with Boehringer Ingelheim strengthens position in personalized eye care market
- Successful pilot phase completion of RDP platform with planned commercial launch in 2025
- Strong global presence with over 50% of employees in key markets (USA, Japan, Spain, France)
- Solid financial performance with €2,066.1m revenue in FY 2023/24
- Established research centers in high-growth markets (India and China)
- High dependency on AI technology adoption and market acceptance
- Significant R&D investments required for AI platform development
- Limited initial market availability with selective country rollout
Showcasing the future of ophthalmic research at ARVO 2025:
- ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows.
- ZEISS's collaboration with Boehringer Ingelheim - championing data-driven, personalized care through ZEISS's ongoing research partnership with Boehringer Ingelheim; hear from industry experts during special presentations at the ZEISS booth #1729 and the Boehringer Ingelheim booth #1629.
JENA, Germany and DUBLIN, Calif., April 30, 2025 /PRNewswire/ -- ZEISS demonstrates a new standard for the future of ophthalmic research at the Association for Research in Vision and Ophthalmology (ARVO) conference, from May 4 – 8, including the introduction of the new ZEISS Research Data Platform (ZEISS RDP), and a spotlight on the ongoing research collaboration with Boehringer Ingelheim to accelerate personalized, data-driven treatment approaches in ophthalmology.
"The future of healthcare is in the data. At ZEISS, we are delivering digital innovation to help shape the future of ophthalmology, investing in research methods that empower clinicians and researchers in balancing their clinical care and research requirements," says Euan S. Thomson, Ph.D., Head of the Digital Business Unit for ZEISS Medical Technology. "The introduction of the ZEISS RDP reflects our commitment to advancing ophthalmic care through smarter, AI-powered tools."
AI technology accelerates discoveries through the ZEISS RDP
At ARVO 2025, ZEISS will introduce the ZEISS RDP, a cloud-based, AI-driven solution designed to transform ophthalmic research workflows. By enabling seamless integration of clinical and research data, ZEISS RDP empowers clinicians and scientists to accelerate discoveries through smarter, more efficient research.
Accelerate research breakthroughs - Using AI-powered tools, clinicians and researchers can swiftly convert their research hypotheses into quantifiable biomarkers. The platform allows users to train their own algorithms and let AI handle complex, time-consuming data analysis, significantly improving efficiency.
Unify research data – Clinicians and researchers can aggregate diverse datasets and formats from multiple sources, facilitating insightful analysis from both medical and surgical imaging data, in addition to other data sources. The platform can consolidate datasets from collaborators while allowing the clinician or research team to retain full control over their data and algorithm with secure user-based access.
Streamline the research workflow – The platform helps clinicians and researchers eliminate silos by integrating research and clinical workflows. Users can automate their data collection from ZEISS FORUM, for example, to reduce manual transfers and errors, increasing overall workflow efficiency.
Following a successful pilot phase, the company plans to launch the ZEISS RDP in select countries throughout 2025.
Ongoing research collaboration with Boehringer Ingelheim
ZEISS Medical Technology and Boehringer Ingelheim continue to advance their research collaboration to champion data-driven artificial intelligence (AI) in the pursuit of earlier detection and prediction capabilities to preserve vision through new treatment pathways and more personalized and precise care for patients with chronic retinal diseases.
"At Boehringer Ingelheim, we're working toward a future in which earlier detection and intervention result in long-term, real-world outcomes that prevent vision loss due to chronic retinal diseases," says Heiko G. Niessen, Ph.D., Global Head of Translational Medicine, Eye Health, at Boehringer Ingelheim. "Our collaboration with ZEISS Medical Technology exemplifies our strategy to work with like-minded partners who share our goal of preserving and protecting eyesight and people's way of life."
ZEISS brings to this collaboration the broad capabilities of its ZEISS Medical Ecosystem – connecting devices and data to enable the development of next-generation analytics, AI technologies, and the potential for new areas of research. Boehringer Ingelheim brings to the collaboration its leading expertise in the discovery and development of breakthrough therapies that transform the lives of people living with underserved medical conditions.
The collaboration between ZEISS and Boehringer Ingelheim will be highlighted during Experts Talks on Wednesday, May 7, at the ZEISS booth #1729 and the Boehringer Ingelheim booth #1629:
- "The Practice of 2030: How Will AI Support You?" presented by Pearse Keane, Professor of Artificial Intelligence at UCL Institute of Ophthalmology & consultant ophthalmologist at Moorfields Eye Hospital,
London . - "How to Tackle Unmet Needs and Treat Diseases Early in the Future?" presented by Sobha Sivaprasad, Professor of Retinal Clinical Research at UCL Institute of Ophthalmology & consultant ophthalmologist at Moorfields Eye Hospital,
London .
"Our partnership with Boehringer Ingelheim personifies our strategic focus to drive innovation through collaboration," adds Thomson. "We're harnessing data ecosystems in new ways, enabling partners like Boehringer Ingelheim to make breakthrough discoveries to combat vision problems and improve people's lives."
ZEISS will showcase its latest technology innovations and a series of poster sessions at the ARVO conference from May 4 - 8, 2025, in
For more information, visit www.zeiss.com/med.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country-specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development. The statements of the healthcare professionals reflect only their personal opinions and experiences and do not necessarily reflect the opinion of any institution that they are affiliated with. The healthcare professionals alone are responsible for the content of their experience reported and any potential resulting infringements. Carl Zeiss Meditec AG and its affiliates to not have clinical evidence supporting the opinions and statements of the health care professionals nor accept any responsibility or liability of the healthcare professionals' content. The healthcare professionals have a contractual or other financial relationship with Carl Zeiss Meditec AG and its affiliates and have received financial support.
Contact for investors
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
Mail: investors.meditec@zeiss.com
Contact for the press
Frank Smith
Head of Global Communications
ZEISS Ophthalmology
Carl Zeiss Meditec Inc.
Phone: +49 3641 220 331
Mail: press.med@zeiss.com
Brief Profile
Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,730 employees worldwide, the Group generated revenue of
The Group's head office is located in Jena,
For further information visit: www.zeiss.com/med
View original content to download multimedia:https://www.prnewswire.com/news-releases/zeiss-unveils-ai-powered-research-data-platform-collaboration-with-boehringer-ingelheim-champions-the-future-of-personalized-eye-care-302442280.html
SOURCE Carl Zeiss Meditec AG
FAQ
What is ZEISS's (CZMWY) new AI Research Data Platform announced at ARVO 2025?
How will the ZEISS-Boehringer Ingelheim partnership affect eye care treatment?
When will ZEISS (CZMWY) launch its Research Data Platform in 2025?
What are the main features of ZEISS's new AI Research Data Platform?
Where can investors see ZEISS's (CZMWY) new AI platform demonstration at ARVO 2025?
